ELAN CORP PLC Form SC 13G July 25, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G			
Under the Securities Exchange Act of 1934			
DOV Pharmaceutical, Inc.			
(Name of Issuer)			
Common Stock, par value \$.0001 per Share			
(Title of Class of Securities)			
259858108			
(CUSIP Number)			
April 24, 2002 (IPO Date) and December 31, 2002			
(Date of Event which Requires Filing of this Statement)			
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:			
/ / Rule 13d-1(b) / / Rule 13d-1(c) /X/ Rule 13d-1(d)			
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.			
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).			
CUSIP 259858108 SCHEDULE 13G -2-			

^{1.} Names of Reporting Persons.

	I.R.S. Identification Nos. of above persons (entities only).					
	Elan Corporation, plc					
2.	Check the Appropriate (See Instructions)	Box i	f a Member of a Group	(a) / / (b) / /		
3.	SEC Use Only					
4.	. Citizenship or Place of Organization Ireland					
		5.	Sole Voting Power			
			0			
	Number of	6.	Shared Voting Power			
	Shares Beneficially		4,044,264			
	Owned by Each	7.	Sole Dispositive Power			
	Reporting Person With:		0			
		8.	Shared Dispositive Power			
			4,044,264			
9.	9. Aggregate Amount Beneficially Owned by Each Reporting Person					
	4,044,264					
10.	. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / /					
11.	.1. Percent of Class Represented by Amount in Row (9)					
	20.4%					
12.	. Type of Reporting Person (See Instructions)					
	СО					
CUSIP	259858108	SCHE	DULE 13G		-3-	
1.	Names of Reporting Pe		of above persons (entities on)	 ly).		

	Elan International Services, Ltd.				
2.	Check the Appropriate (See Instructions)	: ≥ Box i	f a Member of a Group	(a) / / (b) / /	
3.	SEC Use Only				
4.	Citizenship or Place	of Org	anization		
		 5.	Sole Voting Power		
		٠ .	0		
	Number of	6.			
	Shares Beneficially	٠.	4,044,264		
	-				
Owned by Each Reporting		7.	Sole Dispositive Power		
	rerson with:		O		
		8.	Shared Dispositive Power		
			4,044,264		
9.	. Aggregate Amount Beneficially Owned by Each Reporting Person 4,044,264				
10.	. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) //				
11.	. Percent of Class Represented by Amount in Row (9)				
	20.4%				
12.	2. Type of Reporting Person (See Instructions)				
	CO				
CUSIP	259858108	SCHE	DULE 13G		-4-
1.	Names of Reporting Pe		of above persons (entities only)		
	Elan Pharmaceutical 1	Investm	ments Ltd.		
2.	Check the Appropriate	Box i	f a Member of a Group		

(See Instructions)		(a) / / (b) / /	
3. SEC Use Only			
4. Citizenship or Bermuda	Place of	Organization	
	5.	Sole Voting Power	
		0	
Number of	 6.	Shared Voting Power	
Shares Beneficially		1,221,046	
Owned by Each	 7.	Sole Dispositive Power	
Reporting Person With:		0	
	8.	Shared Dispositive Power	
		1,221,046	
10. Check box if the Actions (See Instructions) 11. Percent of Class Re		Amount in Row (9) Excludes Certain Shares / ed by Amount in Row (9)	/
7.2%			
12. Type of Reporting F	Person (S	Gee Instructions)	
CUSIP 259858108	SCHE	EDULE 13G -5	-
Item 1(a). Name of Issuer	c:		
DOV Pharmaceutical,	Inc.		
Item 1(b). Address of Iss	suer's Pr	rincipal Executive Offices:	
433 Hackensack Avenu	ıe, Hacke	ensack, New Jersey 07601	
Item 2(a). Name of Persor	n Filing:		

This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

- (i) Elan Corporation, plc
- (ii) Elan International Services, Ltd.
- (iii) Elan Pharmaceutical Investments Ltd.

Item 2(b). Address of Principal Business Office:

- (i) Elan Corporation, plc Lincoln House, Lincoln Place Dublin 2, Ireland
- (ii) Elan International Services, Ltd.
 102 St. James Court
 Flatts, Smiths
 FL 04 Bermuda
- (iii) Elan Pharmaceutical Investments Ltd.
 102 St. James Court
 Flatts, Smiths FL 04 Bermuda

Item 2(c). Citizenship:

- (i) Elan Corporation, plc is an Irish public limited company
- (ii) Elan International Services, Ltd. is a Bermuda exempted limited liability company
- (iii) Elan Pharmaceutical Investments Ltd. is a Bermuda exempted limited liability company

Item 2(d). Title of Class of Securities:

Common Stock, par value \$.0001 per share (the "Shares")

Item 2(e). CUSIP Number:

259858108

Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:

This Item 3 is not applicable

CUSIP 259858108 SCHEDULE 13G -6-

Item 4. Ownership:

Elan Corporation plc

- (a) Amount beneficially owned: 4,044,264 (1)
- (b) Percent of class: 20.4%
- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote:
 - (ii) shared power to vote or to direct the vote: 4,044,264 (1)
 - (iii) sole power to dispose or to direct

	3 3	
(iv)	the disposition of: shared power to dispose or to direct the disposition of:	4,044,264 (1)
n Inte	rnational Services, Ltd.	
Amoun	4,044,264	
Perce	20.4%	
Numbe	r of shares as to which such person has:	
(ii)	shared power to vote or to direct the vote:	0 4,044,264
(111)	sole power to dispose or to direct the disposition of:	0
(iv)	shared power to dispose or to direct the disposition of:	4,044,264
n Phari	maceutical Investments Ltd.	
Amount beneficially owned:		1,221,046
Perce	7.2%	
Numbe		
	shared power to vote or to direct	0
(iii)	sole power to dispose or to direct	1,221,046
(iv)	shared power to dispose or to direct	1 221 046
	the disposition of:	1,221,046
	n Interval Amount Perces Number (i) (iii) (iv) n Pharm Amount Perces Number (i) (iii) (iii)	(iv) shared power to dispose or to direct the disposition of: In International Services, Ltd. Amount beneficially owned: Percent of class: Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: In Pharmaceutical Investments Ltd. Amount beneficially owned: Percent of class: Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: (iii) sole power to dispose or to direct the vote: (iii) sole power to dispose or to direct the disposition of:

(1) 2,823,218 of the shares are beneficially owned directly by Elan International Services, Ltd., a direct wholly-owned subsidiary of Elan Corporation, plc, and 1,221,046 of the shares are beneficially owned directly by Elan Pharmaceutical Investments Ltd., a direct wholly-owned subsidiary of Elan International Services, Ltd.

CUSIP 259858108 SCHEDULE 13G -8-

Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not Applicable

Item 8. Identification and Classification of Members of the Group:

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10. Certifications:

Not Applicable.

CUSIP 259858108 SCHEDULE 13G -9-

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 25, 2003

ELAN CORPORATION, PLC

By: /s/ Liam Daniel

Name: Liam Daniel Title: Secretary

Dated: July 25, 2003

ELAN INTERNATIONAL SERVICES, LTD.

By: /s/ Kevin Insley

Name: Kevin Insley
Title: President

Dated: July 25, 2003

ELAN PHARMACEUTICAL INVESTMENTS LTD.

By: /s/ Kevin Insley

Name: Kevin Insley
Title: President

CUSIP 259858108 SCHEDULE 13G -10-

EXHIBIT INDEX

Page No.

A. Joint Filing Agreement dated July 25, 2003 by and among Elan Corporation, plc, Elan International Services, Ltd. and Elan Pharmaceutical Investments

Ltd......13

CUSIP 259858108 SCHEDULE 13G -11-

EXHIBIT A
JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of DOV Pharmaceutical, Inc., dated as of July 25, 2003 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

Dated: July 25, 2003

ELAN CORPORATION, PLC

By: /s/ Liam Daniel

Name: Liam Daniel Title: Secretary

Dated: July 25, 2003

ELAN INTERNATIONAL SERVICES, LTD.

By: /s/ Kevin Insley

Name: Kevin Insley Title: President

Dated: July 25, 2003

ELAN PHARMACEUTICAL INVESTMENTS LTD.

By: /s/ Kevin Insley

Name: Kevin Insley
Title: President